NOVELLO, Silvia

NOVELLO, Silvia  

ONCOLOGIA  

Mostra records
Risultati 1 - 20 di 421 (tempo di esecuzione: 0.029 secondi).
Titolo Data di pubblicazione Autore(i) File
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival 2020 Polverari, Giulia; Ceci, Francesco; Bertaglia, Valentina; Reale, Maria Lucia; Rampado, Osvaldo; Gallio, Elena; Passera, Roberto; Liberini, Virginia; Scapoli, Paola; Arena, Vincenzo; Racca, Manuela; Veltri, Andrea; Novello, Silvia; Deandreis, Désirée
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer 2015 Eberhardt W.E.E., De Ruysscher D., Weder W., Le Péchoux C., De Leyn P., Hoffmann H., Westeel V., Stahel R., Felip E., Peters S., Kerr K., Besse B., Vansteenkiste J., Edelman M., Mok T., O'Byrne K., Novello, S., Bubendorf L., Marchetti A., Baas P., Reck M., Syrigos K., Paz-Ares L., Smit E.F., Meldgaard P., Adjei A., Nicolson M., Crinò L., Van Schil P., Senan S., Faivre-Finn C., Rocco G., Veronesi G., Douillard J.-Y., Lim E., Dooms C.
A RANDOMIZED PHASE III TRIAL COMPARING STANDARD AND HIGH-DOSE PEMETREXED AS SECOND-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER. 2008 CULLEN MH; ZATLOUKAL P; SÖRENSON S; S. NOVELLO; FISCHER JR; JOY AA; ZEREU M; PETERSON P; VISSEREN-GRUL CM; ISCOE N
Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Factors affecting diagnostic yield 2007 PRIOLA A.M; PRIOLA S.M; CATALDI A; ERRICO L; DI FRANCO M; CAMPISI P; MOLINARO L; MARCI V; NOVELLO S; C. FAVA
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINEVINORELBINE IN ADVANCED NON SMALL CELL LUNG CANCER ELDERLY PATIENTS. PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY MILES RANDOMISED TRIAL. 2001 GRIDELLI C; CIGOLARI S; GALLO C; MANZIONE L; IANNELLO GP; FRONTINI L; FERRAÙ F; S. NOVELLO; PERRONE F; ON BEHALF OF THE MILES INVESTIGATORS
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. 2014 Landi L;Tiseo M;Chiari R;Ricciardi S;Rossi E;Galetta D;Novello S;Milella M;D'Incecco A;Minuti G;Tibaldi C;Salvini J;Facchinetti F;Haspinger ER;Cortinovis D;Santo A;Banna G;Catino A;GiajLevra M;Crinò L;de Marinis F;Cappuzzo F
Actuality and perspective in the medical treatment of non-small cell lung cancer [Article@Attualità e prospettive nella terapia medica del carcinoma polmonare non-a piccole cellule] 2012 Levra, M.G., Novello, S.
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 2015 Barni, Sandro; Maiello, Evaristo; Di Maio, Massimo; Ardizzoni, Andrea; Cappuzzo, Federico; Maranzano, Ernesto; Novello, Silvia; Bennati, Chiara; Ori, Alessandra; Rizzoli, Sara; Crinò, Lucio
Adjuvant chemotherapy after complete resection for early stage NSCLC 2003 SCAGLIOTTI G ;NOVELLO S
Adjuvant chemotherapy in completely resected Non-small cel lung cancer. 2005 GIORGIO V. SCAGLIOTTI; S. NOVELLO; AND VALTER TORRI
Adjuvant chemotherapy in completely resected Non-Small Cell Lung Cancer, cap 32 2005 GIORGIO V. SCAGLIOTTI; S. NOVELLO; AND VALTER TORRI
Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: Are we actually ready? 2020 Tabbo F.; Reale M.L.; Novello S.
Adjuvant therapy for surgically resected NSCLC: update from ASCO 2004. Selected presentations from the 5th international Lung Cancer , Kauai, Hi July 2004 2004 Scagliotti GV; Novello S.
Adjuvant therapy in completely resected non-small-cell lung cancer 2003 Scagliotti, G.V., Novello, S
Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? 2016 Buffoni, L; Vavalà, T; Novello, S
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. 2014 Gridelli C;de Marinis F;Ardizzoni A;Novello S;Fontanini G;Cappuzzo F;Grossi F;Santo A;Cortinovis D;Favaretto A;Lorusso V;Galetta D;Siena S;Bettini A;Iurlaro M;Caprioli A;LIFE study team
Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey 2017 Bertaglia, V; Vallone, S; Mv, Pacchiana; Novello, S.
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study 2021 Filippo de Marinis, Konstantin K. Laktionov, Artem Poltoratskiy, Inna Egorova, Maximilian Hochmair, Antonio Passaro, Maria Rita Migliorino, Giulio Metro, Maya Gottfried, Daphne Tsoi, Gyula Ostoros, Simona Rizzato, Guzel Z. Mukhametshina, Michael Schumacher, Silvia Novello, Rafal Dziadziuszko, Wenbo Tang, Laura Clementi, Agnieszka Cseh, Dariusz Kowalski
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial. 2012 Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G.
Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy 2018 Vavalà, Tiziana; Novello, Silvia*